tetano
Editor, Senior Moderator
JAMA Intern Med
. 2020 Sep 10.
doi: 10.1001/jamainternmed.2020.5503. Online ahead of print.
Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial
Lin-Ling Cheng[SUP] 1 2 [/SUP], Wei-Jie Guan[SUP] 1 [/SUP], Chong-Yang Duan[SUP] 3 [/SUP], Nuo-Fu Zhang[SUP] 1 [/SUP], Chun-Liang Lei[SUP] 2 [/SUP], Yu Hu[SUP] 4 [/SUP], Ai-Lan Chen[SUP] 5 [/SUP], Shi-Yue Li[SUP] 1 2 [/SUP], Chao Zhuo[SUP] 1 [/SUP], Xi-Long Deng[SUP] 2 [/SUP], Fan-Jun Cheng[SUP] 4 [/SUP], Yong Gao[SUP] 4 [/SUP], Jian-Heng Zhang[SUP] 1 5 [/SUP], Jia-Xing Xie[SUP] 1 5 [/SUP], Hong Peng[SUP] 1 5 [/SUP], Ying-Xian Li[SUP] 1 5 [/SUP], Xiao-Xiong Wu[SUP] 4 [/SUP], Wen Liu[SUP] 4 [/SUP], Hui Peng[SUP] 2 [/SUP], Jian Wang[SUP] 2 [/SUP], Guang-Ming Xiao[SUP] 2 [/SUP], Ping-Yan Chen[SUP] 3 [/SUP], Chun-Yan Wang[SUP] 6 [/SUP], Zi-Feng Yang[SUP] 1 [/SUP], Jin-Cun Zhao[SUP] 1 [/SUP], Nan-Shan Zhong[SUP] 1 [/SUP]
Affiliations
Abstract
Importance: Lymphopenia is common and correlates with poor clinical outcomes in patients with coronavirus disease 2019 (COVID-19).
Objective: To determine whether a therapy that increases peripheral blood leukocyte and lymphocyte cell counts leads to clinical improvement in patients with COVID-19.
Design, setting and participants: Between February 18 and April 10, 2020, we conducted an open-label, multicenter, randomized clinical trial at 3 participating centers in China. The main eligibility criteria were pneumonia, a blood lymphocyte cell count of 800 per μL (to convert to ?109/L, multiply by 0.001) or lower, and no comorbidities. Severe acute respiratory syndrome coronavirus 2 infection was confirmed with reverse-transcription polymerase chain reaction testing.
Exposures: Usual care alone, or usual care plus 3 doses of recombinant human granulocyte colony-stimulating factor (rhG-CSF, 5 μg/kg, subcutaneously at days 0-2).
Main outcomes and measures: The primary end point was the time from randomization to improvement of at least 1 point on a 7-category disease severity score.
Results: Of 200 participants, 112 (56%) were men and the median (interquartile range [IQR]) age was 45 (40-55) years. There was random assignment of 100 patients (50%) to the rhG-CSF group and 100 (50%) to the usual care group. Time to clinical improvement was similar between groups (rhG-CSF group median of 12 days (IQR, 10-16 days) vs usual care group median of 13 days (IQR, 11-17 days); hazard ratio, 1.28; 95% CI, 0.95-1.71; P = .06). For secondary end points, the proportion of patients progressing to acute respiratory distress syndrome, sepsis, or septic shock was lower in the rhG-CSF group (rhG-CSF group, 2% vs usual care group, 15%; difference, -13%; 95%CI, -21.4% to -5.4%). At 21 days, 2 patients (2%) had died in the rhG-CSF group compared with 10 patients (10%) in the usual care group (hazard ratio, 0.19; 95%CI, 0.04-0.88). At day 5, the lymphocyte cell count was higher in the rhG-CSF group (rhG-CSF group median of 1050/μL vs usual care group median of 620/μL; Hodges-Lehmann estimate of the difference in medians, 440; 95% CI, 380-490). Serious adverse events, such as sepsis or septic shock, respiratory failure, and acute respiratory distress syndrome, occurred in 29 patients (14.5%) in the rhG-CSF group and 42 patients (21%) in the usual care group.
Conclusion and relevance: In preliminary findings from a randomized clinical trial, rhG-CSF treatment for patients with COVID-19 with lymphopenia but no comorbidities did not accelerate clinical improvement, but the number of patients developing critical illness or dying may have been reduced. Larger studies that include a broader range of patients with COVID-19 should be conducted.
Trial registration: Chinese Clinical Trial Registry: ChiCTR2000030007.
. 2020 Sep 10.
doi: 10.1001/jamainternmed.2020.5503. Online ahead of print.
Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial
Lin-Ling Cheng[SUP] 1 2 [/SUP], Wei-Jie Guan[SUP] 1 [/SUP], Chong-Yang Duan[SUP] 3 [/SUP], Nuo-Fu Zhang[SUP] 1 [/SUP], Chun-Liang Lei[SUP] 2 [/SUP], Yu Hu[SUP] 4 [/SUP], Ai-Lan Chen[SUP] 5 [/SUP], Shi-Yue Li[SUP] 1 2 [/SUP], Chao Zhuo[SUP] 1 [/SUP], Xi-Long Deng[SUP] 2 [/SUP], Fan-Jun Cheng[SUP] 4 [/SUP], Yong Gao[SUP] 4 [/SUP], Jian-Heng Zhang[SUP] 1 5 [/SUP], Jia-Xing Xie[SUP] 1 5 [/SUP], Hong Peng[SUP] 1 5 [/SUP], Ying-Xian Li[SUP] 1 5 [/SUP], Xiao-Xiong Wu[SUP] 4 [/SUP], Wen Liu[SUP] 4 [/SUP], Hui Peng[SUP] 2 [/SUP], Jian Wang[SUP] 2 [/SUP], Guang-Ming Xiao[SUP] 2 [/SUP], Ping-Yan Chen[SUP] 3 [/SUP], Chun-Yan Wang[SUP] 6 [/SUP], Zi-Feng Yang[SUP] 1 [/SUP], Jin-Cun Zhao[SUP] 1 [/SUP], Nan-Shan Zhong[SUP] 1 [/SUP]
Affiliations
- PMID: 32910179
- DOI: 10.1001/jamainternmed.2020.5503
Abstract
Importance: Lymphopenia is common and correlates with poor clinical outcomes in patients with coronavirus disease 2019 (COVID-19).
Objective: To determine whether a therapy that increases peripheral blood leukocyte and lymphocyte cell counts leads to clinical improvement in patients with COVID-19.
Design, setting and participants: Between February 18 and April 10, 2020, we conducted an open-label, multicenter, randomized clinical trial at 3 participating centers in China. The main eligibility criteria were pneumonia, a blood lymphocyte cell count of 800 per μL (to convert to ?109/L, multiply by 0.001) or lower, and no comorbidities. Severe acute respiratory syndrome coronavirus 2 infection was confirmed with reverse-transcription polymerase chain reaction testing.
Exposures: Usual care alone, or usual care plus 3 doses of recombinant human granulocyte colony-stimulating factor (rhG-CSF, 5 μg/kg, subcutaneously at days 0-2).
Main outcomes and measures: The primary end point was the time from randomization to improvement of at least 1 point on a 7-category disease severity score.
Results: Of 200 participants, 112 (56%) were men and the median (interquartile range [IQR]) age was 45 (40-55) years. There was random assignment of 100 patients (50%) to the rhG-CSF group and 100 (50%) to the usual care group. Time to clinical improvement was similar between groups (rhG-CSF group median of 12 days (IQR, 10-16 days) vs usual care group median of 13 days (IQR, 11-17 days); hazard ratio, 1.28; 95% CI, 0.95-1.71; P = .06). For secondary end points, the proportion of patients progressing to acute respiratory distress syndrome, sepsis, or septic shock was lower in the rhG-CSF group (rhG-CSF group, 2% vs usual care group, 15%; difference, -13%; 95%CI, -21.4% to -5.4%). At 21 days, 2 patients (2%) had died in the rhG-CSF group compared with 10 patients (10%) in the usual care group (hazard ratio, 0.19; 95%CI, 0.04-0.88). At day 5, the lymphocyte cell count was higher in the rhG-CSF group (rhG-CSF group median of 1050/μL vs usual care group median of 620/μL; Hodges-Lehmann estimate of the difference in medians, 440; 95% CI, 380-490). Serious adverse events, such as sepsis or septic shock, respiratory failure, and acute respiratory distress syndrome, occurred in 29 patients (14.5%) in the rhG-CSF group and 42 patients (21%) in the usual care group.
Conclusion and relevance: In preliminary findings from a randomized clinical trial, rhG-CSF treatment for patients with COVID-19 with lymphopenia but no comorbidities did not accelerate clinical improvement, but the number of patients developing critical illness or dying may have been reduced. Larger studies that include a broader range of patients with COVID-19 should be conducted.
Trial registration: Chinese Clinical Trial Registry: ChiCTR2000030007.